Nomura Asset Management
BIVV

Nomura Asset Management’s Bioverativ Inc. Common Stock BIVV Stock Holding History

Nomura Asset Management’s Portfolio BIVV Stock Details BIVV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-12,369
Closed -$674K – 1006
2017
Q1 		$674K Buy
+12,369
New +$609K 0.01% 775

Other funds holding BIVV

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
VH
ValueAct Holdings San Francisco, California $5.71B AUM 7.41% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
WIM
Woodford Investment Management London, United Kingdom $310M AUM 17.41% 1-Year Est. Return

Nomura Asset Management's BIVV Position: Q2 2017 in Review

Nomura Asset Management sold out of Bioverativ Inc. Common Stock (BIVV) in Q2 2017, closing a stake of 12,369 shares — an estimated $674K sold.

Nomura Asset Management first reported a position in BIVV in Q1 2017 and held it in 1 quarter. The position peaked at $674K in Q1 2017. 452 funds tracked by Wall St. Rank hold BIVV as of Q2 2017.

  • Nomura Asset Management reported no remaining Bioverativ Inc. Common Stock position as of Q2 2017 after selling out during the quarter.
  • Nomura Asset Management sold 12,369 Bioverativ Inc. Common Stock shares in Q2 2017, an estimated $674K.
  • Nomura Asset Management first reported a position in Bioverativ Inc. Common Stock in Q1 2017 and held it in 1 quarter.
  • Nomura Asset Management's Bioverativ Inc. Common Stock position peaked at $674K in Q1 2017.
  • 452 funds tracked by Wall St. Rank held Bioverativ Inc. Common Stock as of Q2 2017.

Based on Nomura Asset Management's 13F filing for Q2 2017, filed 14 Aug 2017.